Let's see if this report is confirmed.
GDP-l-fucose synthase is a CD4+ T cell–specific autoantigen in DRB3*02:02 patients with multiple sclerosis
The article is freely available here (https://www.zora.uzh.ch/id/eprint/15883 ... _press.pdf) but there is also a nice review here:
https://davidusharauli.blogspot.com/201 ... l.html?m=1
Multiple sclerosis is an immune-mediated autoimmune disease of the central nervous system that develops in genetically susceptible individuals and likely requires environmental triggers. The autoantigens and molecular mimics triggering the autoimmune response in multiple sclerosis remain incompletely understood.
By using a brain-infiltrating CD4+ T cell clone that is clonally expanded in multiple sclerosis brain lesions and a systematic approach for the identification of its target antigens, positional scanning peptide libraries in combination with biometrical analysis, we have identified guanosine diphosphate (GDP)–l-fucose synthase as an autoantigen that is recognized by cerebrospinal fluid–infiltrating CD4+ T cells from HLA-DRB3*–positive patients. Significant associations were found between reactivity to GDP-l-fucose synthase peptides and DRB3*02:02 expression, along with reactivity against an immunodominant myelin basic protein peptide.
These results, coupled with the cross-recognition of homologous peptides from gut microbiota, suggest a possible role of this antigen as an inducer or driver of pathogenic autoimmune responses in multiple sclerosis.
It seems that the autoimmune system can be re-educated. The same team in Zurich is trying to attach the recently found protein to the blood red cells. It seems that when they enter their final cycle of their lives, the proteins found on them will be used as a re-training for the immune system. It is called "the ETIMS project".
http://www.wysszurich.uzh.ch/projects/w ... /etimsred/
"A team led by Professor Roland Martin already developed an innovative therapy known as ETIMS (Establish Tolerance in MS). This therapy employs the patient’s white blood cells and chemically couples them with myelin peptides. These altered blood cells now target the immune cells responsible for the inflammation and stop the autoimmune process by educating the immune system to tolerate structures such as myelin. This approach has been successfully tested in a first-in-man trial in MS patients."
They have just finished a phase Ib clinical trial and they plan to start a phase IIa in 2019.
Here there is the web for clinical trials of the Zurich university (but only in german)
https://www.multiplesclerosis.uzh.ch/de ... nahme.html
And also interesting some trials about faecal microbiota transplantation:
http://scholar.google.ca/scholar_url?hl ... kQgAMoADAA
- Similar Topics
- Last post
- 0 Replies
- 535 Views
Last post by frodo
Sat Aug 10, 2019 10:13 am